Sherko Kuemmel, Peter A Fasching, Peter Schmid, et al. Ann Surg Oncol. 2026 Feb 25
We prospectively evaluated surgical outcomes following neoadjuvant pembrolizumab or placebo added to neoadjuvant chemotherapy among participants with early-stage triple-negative breast cancer (TNBC) in the phase 3 KEYNOTE-522 stud...
Read More
Andrew N J Tutt, Judy E Garber, Bella Kaufman, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405
New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer. We conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth...
Read More
F Marmé, M Martin, M Untch, et al. ESMO Open. 2024 Jun;9(6):103466
The PENELOPE-B study demonstrated that the addition of 1-year post-neoadjuvant palbociclib to endocrine therapy (ET) in patients with high-risk early breast cancer (BC) did not improve invasive disease-free survival (iDFS) compare...
Read More
Charles E Geyer Jr, Michael Untch, Chiun-Sheng Huang, et al. N Engl J Med. 2025 Jan 16;392(3):249-257
Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primary analysis of KATHERI...
Read More
Charles E Geyer Jr and Sibylle Loibl. Breast. 2025 Jun:81:104450
Reductions in HER2-protein IHC intensity and HER2-gene amplification in residual invasive breast cancer following neoadjuvant therapy for HER2-positive breast cancer have been described and are associated with worse outcomes. T-DM...
Read More
Chiara Dauccia, Maria Alice Franzoi, Samuel Martel, et al Eur J Cancer. 2025 Jun 18:223:115489
We assessed the association of BMI and weight changes with outcomes of patients with HER2-positive early BC included in the APHINITY trial. This is an exploratory analysis of APHINITY (NCT01358877), randomized trial testing adjuva...
Read More
Syed Mahfuz Al Hasan, Debbie L Bennett, Adetunji T Toriola. JAMA Netw Open. 2026 Mar 2;9(3):e263529
Objective: To analyze mammography use trends in US women aged 40 to 49 and 50 to 74 years from 2002 to 2022. Among 2,619,292 US women, mammography use showed a downward trend, with nonsignificant biennial changes of -0.54% for age...
Read More
Anna N Wilkinson, James G Mainprize, Martin J Yaffe, et al. JAMA Netw Open. 2025 Jan 2;8(1):e2452821
Objective: To determine the cost-effectiveness of population-based breast cancer screening in the context of current treatment standards. Incremental cost-effectiveness ratios for deaths averted, life-years (LYs) gained, and incre...
Read More
Syed Mahfuz Al Hasan, Debbie L Bennett, and Adetunji T Toriola. Bull World Health Organ.2025 Aug 1;103(8):470-483
We collected data on breast cancer screening programmes and breast cancer mortality from the World Health Organization's Global Health Observatory, the Global Burden of Diseases 2021 study and the Eurostat database. Between 2015 a...
Read More
Sida Huang, Sarah J Westvold, Pamela R Soulos, et al. JAMA Netw Open. 2025 Apr 1;8(4):e255322
Screening mammography promotes early detection of breast cancer and is associated with reduced breast cancer mortality. Screening history prior to diagnosis may impact stage at diagnosis and breast cancer mortality. Among 13,028 i...
Read More
Javier David Benitez Fuentes, Eileen Morgan, Alicia de Luna Aguilar et al. JAMA Oncol. 2024 Jan 1;10(1):71-78
Objective: To assess the global distribution of breast cancer stage by country, age group, calendar period, and socioeconomic status using population-based data. Data were available for 2.4 million women with breast cancer from 81...
Read More
Yuanyan Tang, Jia Zhu and Zhengren Liu. Cancer Invest. 2025 Sep;43(8):610-622
This study analyzed the trends of BC among Chinese women from 1997 to 2021 to support evidence-based for the prevention, screening and treatment strategies of female BC in China. We extracted data on BC incidence, mortality, preva...
Read More